These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12205066)

  • 1. Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin.
    Weiss K; Guilbault C; Cortes L; Restieri C; Low DE;
    J Antimicrob Chemother; 2002 Sep; 50(3):403-6. PubMed ID: 12205066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A; Koncan R; Vitali LA; Cornaglia G
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides.
    Hoban DJ; Wierzbowski AK; Nichol K; Zhanel GG
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2147-50. PubMed ID: 11408241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.
    Jorgensen JH; Crawford SA; McElmeel ML; Whitney CG
    Antimicrob Agents Chemother; 2004 Feb; 48(2):605-7. PubMed ID: 14742216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci.
    Shortridge VD; Zhong P; Cao Z; Beyer JM; Almer LS; Ramer NC; Doktor SZ; Flamm RK
    Antimicrob Agents Chemother; 2002 Mar; 46(3):783-6. PubMed ID: 11850262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.
    Farrell DJ; Morrissey I; Bakker S; Felmingham D
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():39-47. PubMed ID: 12239227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of erythromycin-resistant Streptococcus pneumoniae in Korea, and In Vitro activity of telithromycin against erythromycin-resistant Streptococcus pneumoniae.
    Kim NJ; Park SJ; Choi SH; Lee MS; Choo EJ; Kwak YG; Woo JH; Ryu J; Jeong JY; Kim YS
    Microb Drug Resist; 2005; 11(3):260-5. PubMed ID: 16201929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.
    Davies TA; Kelly LM; Jacobs MR; Appelbaum PC
    J Clin Microbiol; 2000 Apr; 38(4):1444-8. PubMed ID: 10747123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.
    Farrell DJ; Jenkins SG
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i17-22. PubMed ID: 15265832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children.
    Johnson CN; Benjamin WH; Gray BM; Crain MC; Edwards KM; Waites KB
    Int J Antimicrob Agents; 2001 Dec; 18(6):531-5. PubMed ID: 11738340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
    Jenkins SG; Brown SD; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of a novel ketolide ABT-773 against invasive strains of Streptococcus pneumoniae.
    Weiss K; de Azavedo J; Restieri C; Quach C; Laverdiere M; Rubin E; Gourdeau M; Low DE
    J Antimicrob Chemother; 2001 Sep; 48(3):407-9. PubMed ID: 11533007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.
    Jenkins SG; Farrell DJ; Patel M; Lavin BS
    J Infect; 2005 Dec; 51(5):355-63. PubMed ID: 15950288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
    Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study.
    Schito GC; Marchese A; Elkharrat D; Farrell DJ;
    J Chemother; 2004 Feb; 16(1):13-22. PubMed ID: 15077994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.
    Mazzariol A; Koncan R; Bahar G; Cornaglia G
    J Chemother; 2007 Oct; 19(5):500-7. PubMed ID: 18073148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
    Matic V; Kosowska K; Bozdogan B; Kelly LM; Smith K; Ednie LM; Lin G; Credito KL; Clark CL; McGhee P; Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4103-12. PubMed ID: 15504828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms.
    Morosini MI; Cantón R; Loza E; Negri MC; Galán JC; Almaraz F; Baquero F
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2427-31. PubMed ID: 11502509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae.
    Walsh F; Willcock J; Amyes S
    J Antimicrob Chemother; 2003 Sep; 52(3):345-53. PubMed ID: 12917252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.